Pharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator.

Abstract:

:The pharmacokinetics of a new selective oestrogen receptor modulator levormeloxifene was investigated in mice, rats, cynomolgus monkeys and humans by compartmental pharmacokinetics. Levormeloxifene was administered as an oral solution in all studies. Allometric scaling was used to predict human pharmacokinetic parameters and the performance of the approach was evaluated. Mean values of clearance confounded by F(CL/F) were 0.073, 0.29, 3.18 and 2.4 l/h in mice, rats, monkeys and humans, respectively. Values of distribution volume at steady state confounded by F(V(ss)/F) were 0.073 and 7.5 l in mice and rats. In monkeys, values of the central volume F(V(c)/F) and volume at steady state F(V(ss)/F) were 28.9 and 57.9 l, respectively. In humans, values of V(c)/F and V(ss)/F were 106 and 587 l, respectively. Predicted CL/F and V(ss)/F showed a linear relationship when plotted vs BW on a log-log scale; for CL/F, r was 0.95-0.98 and for V(ss)/F, r was 0.99. Using allometric scaling the predicted human V(ss)/F deviated 3-fold from the experimentally determined values. Observed values of CL/F deviated 21-25 fold from the predicted, the latter depending on the scaling method. Confidence intervals for the predicted parameters showed major lack of precision for all the allometric scaling methods.

journal_name

Biopharm Drug Dispos

authors

Østerberg O,Kiehr B,Erichsen L,Poulsen HE,Ingwersen SH

doi

10.1002/bdd.344

keywords:

subject

Has Abstract

pub_date

2003-04-01 00:00:00

pages

121-9

issue

3

eissn

0142-2782

issn

1099-081X

journal_volume

24

pub_type

杂志文章
  • Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice.

    abstract::We synthesized 14C-warfarin hexadecyl ether (14C-WHE) by addition of a palmityl moiety to the hydroxyl group at the 4-position of 14C-warfarin, a compound known to bind to serum albumin. 14C-WHE preferentially bound to the lipoproteins, low-density lipoprotein (LDL) and high-density lipoprotein (HDL), in mouse plasma ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510160204

    authors: Tokui T,Kuroiwa C,Muramatsu S,Tokui Y,Sasagawa K,Ikeda T,Komai T

    更新日期:1995-03-01 00:00:00

  • Drug and metabolite concentrations combined in predicting steady-state concentrations from test doses.

    abstract::The first day test dose versus steady-state relationship for predicting drug doses was evaluated for the situation where metabolites are produced. An organ clearance model incorporated into a digital computer program simulated drug and metabolite disposition. When the terminal elimination rate for metabolite was simil...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510040105

    authors: Devane CL,Jusko WJ

    更新日期:1983-01-01 00:00:00

  • Theophylline controlled-release formulations: in vivo-in vitro correlations.

    abstract::Four experimental controlled-release oral solid dosage formulations were developed and the in vitro dissolution characteristics of theophylline from these formulations were studied in USP apparatus I. Pharmacokinetic evaluation of these formulations was carried out in eight beagle dogs under fasting conditions. Theoph...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/(SICI)1099-081X(199604)17:3<259::AID-BDD95

    authors: Yu Z,Schwartz JB,Sugita ET

    更新日期:1996-04-01 00:00:00

  • Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers.

    abstract::Aim. To study the pharmacokinetics of dihydroartemisinin (DHA) in Artekin (compound dihydroartemisinin) tablets in Chinese healthy volunteers. Methods. Eighteen healthy volunteers (9 males, 9 females) received Artekin tablets for oral administration. The plasma samples of DHA were analysed by liquid-liquid extraction ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.607

    authors: Hong X,Liu CH,Huang XT,Huang TL,Ye SM,Ou WP,Wang NS,Mi SQ

    更新日期:2008-05-01 00:00:00

  • The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers.

    abstract::The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg were investigated ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(sici)1099-081x(199910)20:7<327::aid-bdd19

    authors: Kanerva H,Kilkku O,Heinonen E,Helminen A,Rouru J,Tarpila S,Scheinin M,Huupponen R,Klebovich I,Drabant S,Urtti A

    更新日期:1999-10-01 00:00:00

  • Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.

    abstract:PURPOSE:The chromone derivative MBL-II-141, specifically designed to inhibit ABCG2, was previously demonstrated to combine strong inhibition potency, low toxicity and good efficiency in reversing resistance to irinotecan in a xenografted mouse model. Here, the pharmacokinetic interactions in mice between irinotecan, it...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2069

    authors: Hénin E,Honorat M,Guitton J,Di Pietro A,Payen L,Tod M

    更新日期:2017-07-01 00:00:00

  • Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat.

    abstract::The pharmacokinetics of 3-(decyldimethylsilyl)-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide (DMPP), an inhibitor of acyl-CoA:cholesterol acyltransferase, have been studied in the dog and the rat using 14C and 3H dual-labelled drug. In both species, gastrointestinal absorption of DMPP was slow and incomplete, amount...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510080504

    authors: Tse FL,Jaffe JM

    更新日期:1987-09-01 00:00:00

  • The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers.

    abstract::This study was conducted to determine the relative bioavailability of Dilacor XR capsules compared to Cardizem CD capsules at both low (180 mg d-1) and high (540 mg d-1) dose levels. Trough and serial plasma samples were obtained and pharmacokinetic parameters were calculated from the steady state concentration-time p...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(SICI)1099-081X(199601)17:1<43::AID-BDD935

    authors: Lippert CL,Arumugham T,Bhargava VO,Eller M,Weir SJ

    更新日期:1996-01-01 00:00:00

  • Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons.

    abstract::The antimalarial drug, halofantrine, is chiral and is administered clinically as the racemate. In order to define the pharmacokinetic properties of halofantrine enantiomers in the rat, male Sprague-Dawley rats (264-311 g) were given halofantrine HCl orally (n = 5; 14 mg/kg) or intravenously (i.v.) (n = 5; 2 mg/kg). Pl...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-081x(199904)20:3<165::aid-bdd17

    authors: Brocks DR,Toni JW

    更新日期:1999-04-01 00:00:00

  • Quantification and prediction of skin pharmacokinetics of amoxicillin and cefuroxime.

    abstract::The purpose of this project was to develop and validate a pharmacokinetic model and to quantify the rate and extent of distribution between plasma and skin of two beta-lactam antibiotics, amoxicillin (AMX) and cefuroxime (CFX), which are frequently administered systemically to treat skin and skin structure infections....

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.658

    authors: Shukla C,Patel V,Juluru R,Stagni G

    更新日期:2009-09-01 00:00:00

  • Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations.

    abstract::Prednisolone (POH) and prednisone (PO) were both administered via seven different intravenous infusions (three POH and four PO) in each of six rabbits to obtain steady state. Bolus doses of POH and PO were also administered to four of the rabbits. Plasma samples of POH and PO were analyzed by normal phase HPLC. Unboun...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510120608

    authors: Hammarlund-Udenaes M,Benet LZ

    更新日期:1991-08-01 00:00:00

  • Metabolism of steroids by cytochrome P450 2C9 variants.

    abstract::CYP2C9 is a human microsomal cytochrome P450c (CYP). Much variation in CYP2C9 levels and activity can be attributed to polymorphisms of this gene. Wild-type CYP2C9 and ten mutants were co-expressed with NADPH-cytochrome P450 reductase in Escherichia coli. The hydroxylase activities toward steroids were examined. CYP2C...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2153

    authors: Uno T,Nakano R,Kitagawa R,Okada M,Kanamaru K,Takenaka S,Uno Y,Imaishi H

    更新日期:2018-09-01 00:00:00

  • Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.

    abstract::Many marketed drugs are chiral and are administered as the racemate, a 50:50 combination of two enantiomers. Pharmacodynamic and pharmacokinetic differences between enantiomers are well documented. Because of enantioselectivity in pharmacokinetics, results of in vitro pharmacodynamic studies involving enantiomers may ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章,评审

    doi:10.1002/bdd.517

    authors: Brocks DR

    更新日期:2006-11-01 00:00:00

  • The effect of chronic retrovirus infection and immune dysfunction on the P-450-mediated activation of acetaminophen in mouse liver microsomes.

    abstract::Acute viral infection has long been recognized to down-regulate cytochrome P-450 enzymes and subsequently to result in changes in the pharmacological and toxicological responses to xenobiotics. In our previous research, chronic retrovirus infection induced by inoculating a susceptible strain of mice with LP-BM5 murine...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-081x(199801)19:1<9::aid-bdd70>3

    authors: Chow HH,Tang Y,Li P,Brookshier G,Liang B,Watson R

    更新日期:1998-01-01 00:00:00

  • Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects.

    abstract::The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100 mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For dose-proportionality, AUC, and Cmax-dose relationships were evaluated by linear ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510140403

    authors: De Vries MH,Van Harten J,Van Bemmel P,Raghoebar M

    更新日期:1993-05-01 00:00:00

  • Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.

    abstract::Dihydroergotoxine is a mixture of semi-synthetic ergot alkaloids mainly used for age-related cognitive impairment. In this study, dihydroergotoxine (30 microM) was added to incubates of rat and bovine liver microsomes, and the resulting major metabolites were identified as hydroxy-dihydroergocornine, hydroxy-dihydroer...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.585

    authors: Bicalho B,Giolo JM,Lilla S,De Nucci G

    更新日期:2008-01-01 00:00:00

  • In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion.

    abstract::A semisolid self-emulsifying system (SES) of itraconazole consisting of oleic acid, polysorbate 80 and coajuvant (citric acid) was prepared by a hot-melt technique and then compared with hydroxypropylmethylcellulose (HPMC) solid dispersion (SD) coated onto inert sugar spheres as a reference formulation for in vitro an...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.546

    authors: Park MJ,Ren S,Lee BJ

    更新日期:2007-05-01 00:00:00

  • Biotransformation and urinary excretion of 4-substituted amphetamines in pregnant mice.

    abstract::The urinary elimination of 4-hydroxyamphetamine (PHA) and a series of homologous 4-alkoxy-substituted amphetamines and their metabolites was examined after single and multiple oral administration to pregnant and non-pregnant mice. The metabolic profile and extent of biotransformation in a series of alkoxy analogues we...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510140807

    authors: Foster BC,Litster DL,Buttar HS,Dawson B,Zamecnik J

    更新日期:1993-11-01 00:00:00

  • Pharmacokinetic and metabolism studies using uniformly stable isotope labeled proteins with HPLC/CRIMS detection.

    abstract::We present a novel method for performing pharmacokinetic and metabolism studies on macromolecules that offers advantages over the existing techniques of radiolabeling, immunoassay or bioassays. Our strategy uses macromolecules with stable isotopes uniformly distributed throughout the structure. The stable isotope enri...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-081x(199810)19:7<439::aid-bdd12

    authors: Osborn BL,Abramson FP

    更新日期:1998-10-01 00:00:00

  • Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats.

    abstract::The study examined the effect of doxorubicin (DOX) on the hepatic expression of CYP2C and its activity for metabolizing tolbutamide (TB), a specific CYP2C substrate, in rats and whether the pharmacokinetics of tolbutamide were altered by doxorubicin exposure. The expression level of hepatic CYP2C11 was depressed 1 day...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2195

    authors: Fukuno S,Nagai K,Yamamoto K,Tanimura T,Nabe T,Konishi H

    更新日期:2019-07-01 00:00:00

  • Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.

    abstract::Lumefantrine has been reported to be mainly bio-transformed by cytochrome P450 isozyme 3A4 to desbutyl-lumefantrine (DLF) in human liver microsomes. Since CYP3A is expressed in a sex specific manner in rats, it could be expected that the pharmacokinetics of lumefantrine would be changed in male rats compared with thos...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1786

    authors: Wahajuddin,Singh SP,Jain GK

    更新日期:2012-05-01 00:00:00

  • A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.

    abstract::Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using a physiologically based pharmacokinetic approach integrating demographic and physiological data from patients with cancer. Demographic data such as age, sex and body weight, and clinical laboratory ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1830

    authors: Cheeti S,Budha NR,Rajan S,Dresser MJ,Jin JY

    更新日期:2013-04-01 00:00:00

  • The absorption, distribution, metabolism and elimination of bevirimat in rats.

    abstract::Bevirimat is the first drug in the class of maturation inhibitors, which treat HIV infection by disrupting the activity of HIV protease enzyme with a mechanism of action distinct from that of conventional protease inhibitors. The absorption, distribution, metabolism and elimination characteristics of single intravenou...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.625

    authors: Bullock P,Larsen D,Press R,Wehrman T,Martin DE

    更新日期:2008-10-01 00:00:00

  • The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers.

    abstract::Sildenafil is the first oral therapeutic agent for the management of male erectile dysfunction. Its oral bioavailability is only 40% due to extensive presystemic elimination, mainly by CYP3A4. This study examined the effect of coadministration of ciprofloxacin or clarithromycin, which inhibit CYP3A4, on the bioavailab...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.488

    authors: Hedaya MA,El-Afify DR,El-Maghraby GM

    更新日期:2006-03-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.

    abstract::The pharmacokinetics and pharmacodynamics of furosemide were investigated after intravenous (i.v.), 1 mg/100 g body weight, and oral administration, 2 mg per 100 g body weight, to spontaneously hypertensive rats (SHRs) and deoxycorticosterone acetate-salt-induced hypertensive rats (DOCA-salt rats). After i.v. administ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510150302

    authors: Jang SH,Lee MG,Kim ND

    更新日期:1994-04-01 00:00:00

  • A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic.

    abstract::The pharmacokinetics of didanosine and ciprofloxacin were evaluated following the administration of multiple oral doses of each drug as a single agent or in combination. Didanosine was dosed as the Videx chewable/dispersible tablet, which contains the antacids dihydroxyaluminum sodium carbonate and magnesium hydroxide...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(sici)1099-081x(199701)18:1<65::aid-bdd13>

    authors: Knupp CA,Barbhaiya RH

    更新日期:1997-01-01 00:00:00

  • Concentration-dependent clearance of procainamide in normal subjects.

    abstract::Four normal volunteers each received two intravenous doses of PA. The mean low dose was 3.30 mg kg-1 (infused over 20 minutes) while the mean high dose was 12.5 mg kg-1 (infused over 60 minutes). Blood samples were collected for 12 hours and urine was collected for 48 hours after each dose. PA concentrations were dete...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510060207

    authors: Coyle JD,Boudoulas H,Mackichan JJ,Lima JJ

    更新日期:1985-04-01 00:00:00

  • Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.

    abstract::A major component of physiologically based pharmacokinetic (PBPK) models is the prediction of the rate and extent of absorption of orally dosed drugs for which knowledge of effective passive intestinal permeability (Peff ) is essential. Single-pass intestinal perfusion (SPIP) studies are used to establish effective pe...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2072

    authors: Pade D,Jamei M,Rostami-Hodjegan A,Turner DB

    更新日期:2017-03-01 00:00:00

  • Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.

    abstract::Methotrexate (MTX) is an antifolate agent used in the treatment of numerous types of cancer, and eliminated by active tubular secretion via organic anion transporter 3 (OAT3). Gastric antisecretory drugs, such as proton pump inhibitors (PPIs) and histamine H2 receptor antagonists, are widely used among patients with c...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2091

    authors: Narumi K,Sato Y,Kobayashi M,Furugen A,Kasashi K,Yamada T,Teshima T,Iseki K

    更新日期:2017-12-01 00:00:00

  • Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.

    abstract::The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4), that are drug efflux transporters ex...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1801

    authors: Nagasaka Y,Oda K,Iwatsubo T,Kawamura A,Usui T

    更新日期:2012-09-01 00:00:00